Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
Sanofi’s participation will support the progression of Sensorion’s genetic medicine pipeline.
Cytiva Navigating cell therapy WP 4
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s
FDA increases manufacturing flexibility for cell and gene therapies
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Alternative commercialisation models offer lifeline to future of gene therapies
Cell and gene therapy investment strategy pivots as funding dries up
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
